Booster Shots and Additional Doses for COVID-19 Vaccines — What You Need to Know | Johns Hopkins Medicine
![Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/asset/cb26e910-dc14-4b32-a123-110b22c44f1e/gr1.jpg)
Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study - The Lancet Respiratory Medicine
![Covid spring booster 2023: Everything you need to know - Department of Health and Social Care Media Centre Covid spring booster 2023: Everything you need to know - Department of Health and Social Care Media Centre](https://healthmedia.blog.gov.uk/wp-content/uploads/sites/169/2023/04/Blog_Official_Graphic-03-1-1.jpg)
Covid spring booster 2023: Everything you need to know - Department of Health and Social Care Media Centre
![Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://www.thelancet.com/cms/attachment/966d70c5-8395-4ea2-9a35-94dc18f2f550/gr1.gif)
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig1_HTML.png)